Naturex announced the launch of Flowens™, a full-spectrum cranberry-based ingredient specifically developed for men’s health. This optimized formula is supported by gold standard clinical evidence illustrating its ability to improve lower urinary tract health.
More than 50 percent of men in their 50s and 80 percent of men in their 70s suffer from poor urinary tract health. Men are proactively seeking solutions to alleviate symptoms and improve their overall quality of life. Besides pharmaceutical drugs, plant-based solutions consistently rank within the top 10 for overall nutritional supplement sales in the U.S. However, the effectiveness of leading phytotherapies has come under scrutiny underscoring the need for an effective product like Flowens.
In a double-blind, randomized, placebo-controlled intervention study, 250 mg or 500 mg of Flowens consumed once daily showed statistically significant improvements in the key clinical marker for urinary tract health by up to 44 percent. Both doses also showed statistically significant improvements in uroflowmetry markers such as post-void residual volume (PRV) and bladder volume (VOL).
Today’s baby boomers are searching for new and effective natural alternatives to pharmaceutical drugs for relief from uncomfortable LUTS. “The leading prostate nutritional supplement ingredient was the subject of a failed NCCAM (National Center for Complementary and Alternative Medicine) study and a negative Cochrane Review. The market is in need of a safe and clinically substantiated ingredient like Flowens,” said Dan Souza, senior director of sales and marketing for NATUREX-DBS. “Flowens delivers gold-standard clinical results without the unwanted sexual side effects commonly associated with pharmaceutical drugs and the current phytotherapy. Flowens was also very well received by participants in the study. More than 96 percent of the subjects who observed symptom improvements (frequency, urge incontinence, weak stream, urinary retention, etc.) would recommend Flowens to a friend,” he added.